IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a $3.00 price objective on the stock.

Separately, Alliance Global Partners raised their target price on shares of IceCure Medical from $1.90 to $2.90 and gave the company a buy rating in a research note on Wednesday, March 20th.

IceCure Medical Stock Down 1.3 %

ICCM opened at $0.73 on Tuesday. The firm has a market capitalization of $33.30 million, a P/E ratio of -2.21 and a beta of 0.57. IceCure Medical has a one year low of $0.52 and a one year high of $1.57. The company has a fifty day moving average price of $0.95 and a 200-day moving average price of $1.15. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.39 and a quick ratio of 2.88.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Tuesday, May 28th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. The business had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.80 million. During the same period in the previous year, the business earned ($0.08) earnings per share. Equities research analysts expect that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.